Prior to this publication I had posited that PD-L1 (receptor for PD-1) inhibition by leronlimab may be sufficient enough that a PD-1 inhibitor like Keytruda may be unnecessary. But it was unknown how well CCR5 blockade could downregulate PD-L1. This study showed how dramatic the effect could be. The study was done with maraviroc which is less effective than leronlimab. The results support that a PD-1 inhibitor would be unnecessary.

https://jitc.bmj.com/content/8/1/e000228